NCT03929120View on ClinicalTrials.gov

Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

July 27, 2021

Study Completion Date

February 2, 2022

Conditions
Interstitial Lung DiseaseConnective Tissue Diseases
Interventions
BIOLOGICAL

Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)

Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.

Trial Locations (1)

32224

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT03929120 - Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD) | Biotech Hunter | Biotech Hunter